London, UK, 28 September 2017 - Edison Investment Research, the investment research and advisory company, today announces the release of its independent and detailed analyst report into the rapidly evolving area of T-cell cancer therapies. In two parts, the free report looks at the potential and limitations of current CAR-T approaches for addressing the majority of tumor types. It provides analysis on current events in the CAR-T sector, as well as available technologies, challenges, solutions and predictions for the future of T-cell therapies overall.
The release of the report follows the fast pace of recent developments including the rapid US approval of the first T-cell therapy (Novartis’ Kymriah, a CAR-T), the likely US approval of a second CAR-T therapy from Kite Pharma and the acquisition of Kite Pharma by Gilead Sciences for USD 12 billion. The report is aimed at a variety of stakeholders in the CAR-T field, including investors, development firms, academia, regulators, government and public sector bodies, and the wider market.
“Investors have understandably focused onto the dramatic success and rapid US approval of Kymriah but investors and developers need to take a wider and longer-term perspective and look at other cancers and T-cell technologies as well. This report gives an intelligible route map based on a deep understanding of the technical fundamentals,” said Neil Shah, Director of Research, Edison Investment Research. “Investors and those right across the market confused by the blizzard of clinical detail and needing an understandable and independent perspective should read this report. Edison makes its content freely available to provide the fundamental analytical information needed by investors and the media.”
The report is in two parts – the first part is a review of the challenges and potential of the different approaches in T-cell therapy including current CAR-T and other T-cell based approaches. Part two gives an indepth balanced review of the various technologies looking at their potential but also their risks and uncertainties. The report was written by two leading healthcare analysts Dr John Savin and Dr Daniel Wilkinson.
The report details a number of key conclusions: Kymriah and other expected first wave CD19-targeting CAR-T therapies only cover 1.4 percent of cancers in the US and about 1 percent of deaths. Due to the success of CAR-T in leukaemia, 53 percent of T-cell clinical trials are aimed at the 10 percent of patients with blood cancers. Few clinical trials are seeking to extend T-cell therapy to patients who are diagnosed with major solid cancers annually. These patients number 1.2 million in the US alone.
The reason for the mismatch between investment and medical need is that CAR-T technology is very hard to adapt to attack solid cancers. The two most likely current options for extending T-cell therapy to treat solid tumors are NKR CAR T-cell therapy and T-cell receptor (TCR) approaches. Both may advance rapidly if they show promising results. As solid cancers are difficult to attack, T-cell therapies might be combined with checkpoint inhibitors - as already used to treat lung and skin cancers - and BiTEs.
“The challenge for T-cell therapy is to break out from the current limited niche to deliver real therapeutic change in the bigger blood cancers and especially in solid cancer therapy. That is where most of the patients are and the most medical needs arise. There are major questions as to whether these T-cell therapies work beyond their current limited niche and if they can be made affordable,” said Dr John Savin, lead author “The entire market is still learning about T-cell therapies so decisions and outcomes are uncertain, which is why Edison has dedicated resources to examine all available evidence. There are really difficult medical, commercial and logistical challenges ahead. However, the potential for major treatment advances is becoming visible and considerable opportunities are emerging.”
Click here to view the full report.
All reports published by Edison are available to download free of charge from its website: www.edisoninvestmentresearch.com.
About Edison
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorized and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.
For more information please contact Edison:
Dennis Hulme, +61 (0)2 9258 1161
Juan Pedro Serrate, +44 (0)20 3681 2534
healthcare@edisongroup.com
Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn https://www.linkedin.com/company/edison-investment-research
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
